Treatment Options After CAR T Therapy for Large B-Cell Lymphoma
The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.
Using CAR T Therapy and Other Novel Treatments for Non-Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD, discussed the potential of using non–CAR T-based novel approaches in the non-Hodgkin lymphoma treatment paradigm.
Tackling Dravet Syndrome With Gene Therapy
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.
iPSC-Derived NK Cell Agents Show Benefit in B-Cell Malignancies
FT516 and FT595 are both currently being evaluated in phase 1 trials for B-cell malignancies.
IND Cleared for New CAR T-Cell Therapy in Large B-Cell Lymphoma
KITE-363 is set to be investigated in a phase 1 clinical trial at the end of 2021.
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Approval
The 2-dose vaccine has been approved for use 9 months after its Emergency Use Authorization (EUA).
Treating Endothelial Disease With One Cornea Donor
Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Later-Generation Cell Therapies Increase Utility in Hematologic Malignancies
CAR T-cell therapy use will likely expand to a wider array of hematologic malignancies.
Using CAR T Therapy in R/R Multiple Myeloma
Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
A Review of Autologous Stem Cell Transplantation in Amyloidosis
Iuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.
Ide-Cel Approved in EU for Relapsed/Refractory Multiple Myeloma
The FDA previously approved ide-cel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.
Recognizing and Managing AEs in CAR T-Cell Therapy
Kelly Garvin, BSN, RN, OCN, discussed methods to communicate the benefits and risks of CAR T-cell therapy to patients and recognize AEs.
Selecting AAV Manufacturing Platforms
The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.
Mustang Bio, Mayo Clinic Collaborate on New CAR T Platform
Mustang Bio plans to file an IND and start a phase 1 clinical trial as soon as a lead construct is identified.
JQ1, a BET Inhibitor, Increases CAR T Efficacy and Durability
Investigators sought to understand the mechanisms of transferred T cell proliferation and expression.
Developing Oncolytic Cell Therapies With VISION
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.
Immunotherapy as Single Agent, Combination Therapy for Multiple Myeloma
Krina K. Patel, MD, MSc, discussed moving away from chemotherapy and toward immunotherapy.
Bringing Gene Therapies to Market With the Help of MEAs
With a new paradigm of treating previously incurable diseases comes a new pay paradigm for million-dollar therapies.
Future Research in Gene and Cell Therapy Conditioning
Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Ongoing Research Supports CAR T Therapy's Use in Non-Hodgkin Lymphoma
Julie Vose, MD, professor of internal medicine and division chief, Division of Oncology and Hematology, University of Nebraska Medical Center, discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.
CAR T Therapy ALLO-715 Receives Orphan Drug Designation for Multiple Myeloma
The ongoing phase 1 UNIVERSAL trial has demonstrated an overall response rate of 60% among 10 patients.
FDA Lifts Hold on Danon Disease Gene Therapy
Rocket Pharmaceuticals plans to quickly resume the phase 1 trial and commence dosing in their new, low-dose, pediatric cohort in Q3 2021.
Immunotherapy and CAR T-Cell Therapy: Stephen M. Ansell, MD, PhD
The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.
The Potential of CRISPR Therapies in Retinal Disorders
Targeted CRISPR therapy has potential in treating inherited retinal diseases.
Challenges With CAR T Therapy in Follicular Lymphoma: Sattva S. Neelapu, MD
The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.
Future Research With CAR T in Lymphoma: Julie Vose, MD
The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.
Gene Therapy for Wilson Disease Receives FDA Fast Track Designation
A phase 1/2 study evaluating Vivet Therapeutic’s VTX-801 is set to initiate in August 2021.
Targeting LHON and Retinitis Pigmentosa With Gene Therapy
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.
Managing CAR T Therapy Toxicities With Standardized Care Guidelines
David G. Maloney, MD, PhD, covered the importance of standardized criteria in managing CRS and ICANS with CAR T therapy.
Allogeneic vs Autologous CAR T-Cell Therapies
The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.
